Who benefits most from the efficiency advancements though?
Governments seem to benefit most as they effectively determine the margin on testing through regulated pricing. Best example of this being Australian pathology Medicare pricing not changing in 20 years. The company invests in technology to improve efficiency/cost and the public and government mostly reap the rewards. It's a good win for society.
Ann: Half Yearly Report and Accounts, page-37
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$25.75 |
Change
0.270(1.06%) |
Mkt cap ! $12.37B | |||
| Open | High | Low | Value | Volume |
| $25.50 | $25.79 | $25.46 | $23.72M | 923.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3392 | $25.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.76 | 612 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |